Clinical Trials Logo
  1. Home
  2. Neoadjuvant Therapy
  3. NCT05223582

Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial

Neoadjuvant Therapy Clinical Trial

Official title:
Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial

Clinical Trial Summary

The aim of this study is to evaluate the safety and efficacy of fluzoparib combined with abiraterone in neoadjuvant treatment of patients with high-risk locoregional prostate cancer. Dr. Yao Zhu from Fudan University Shanghai Cancer Center is the co-leading PI of this study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05223582
Study type Interventional
Source Fudan University
Contact
Status Active, not recruiting
Phase Phase 2
Start date May 1, 2021
Completion date December 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05161572 - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Phase 2
Not yet recruiting NCT05996484 - Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma Phase 2
Not yet recruiting NCT04520737 - Multimodal Prehabilitation During Chemotherapy in Patients With Colorectal Liver Metastases N/A
Recruiting NCT06138496 - Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC Phase 2
Not yet recruiting NCT05983094 - Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer Phase 2
Terminated NCT04440982 - Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients Phase 2
Recruiting NCT04028375 - Study of CT and MR in the Gastric Cancer
Active, not recruiting NCT03192735 - Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer Phase 2
Recruiting NCT04588987 - Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma Phase 2
Not yet recruiting NCT05993858 - Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC Phase 2
Active, not recruiting NCT04666090 - Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT04848454 - Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy Phase 2
Recruiting NCT04062058 - A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer Phase 2
Recruiting NCT06124378 - Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer Phase 2
Not yet recruiting NCT06125223 - PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma
Not yet recruiting NCT06404736 - QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer Phase 2
Not yet recruiting NCT06404463 - QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer Phase 2
Recruiting NCT05371197 - Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer Phase 2
Recruiting NCT06212440 - Clinical Application of Multi-modal Sentinel Lymph Node Staining Method in Breast Cancer Patients After Neoadjuvant Chemotherapy N/A
Completed NCT03178032 - Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas Phase 1